Sales & Earnings In Brief
Drugstore.com reworks Medco partnership: Revenues from drugstore.com's strategic alliance with Medco Health Solutions reaches "well below expectations" in the second quarter, and the Bellevue, Wash., retailer dials down 2010 projected revenues from the partnership to a range of $16 million to $20 million, from previous guidance of $30 million to $60 million, CEO Dawn Lepore says. Revenue sharing on the Medco Health Store venture, which has 1.4 million registered members, will change to a cost-plus model from a contribution margin split arrangement to give Medco more flexibility in pricing and ensure greater financial return for drugstore.com, Lepore said. The firms announced Aug. 3 their OTC retail alliance will continue through 2018 (1"The Tan Sheet" Jan. 18, 2010). Another "key growth initiative" for drugstore.com, its microsite strategy, is rapidly increasing sales, Lepore said, with six microsites launched in the past 10 months. During an earnings call, executives were positive about the firm's OTC performance - net sales in the category climbed 34.5 percent to $95.9 million in the quarter ended July 4 and 31.7 percent to $188.9 million in the half. Net losses of $2.7 million in the quarter and $5.3 million in the half, compared to profits of $1 million and $1.9 million, reflected increased costs and the loss of revenue from divested operations
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.